Alector, Inc. (ALEC) Form 8-K — Aug 6, 2026
Alector reported second quarter 2026 results on August 6, 2026, with a net loss of $23.0 million, or $0.21 per share, narrowed from $30.5 million, or $0.30 per share, a year earlier. Collaboration revenue fell to $3.3 million from $7.9 million, mainly on lower revenue recognized for the AL101 Alzheimer's program. Expenses dropped sharply following prior reductions in force, with R&D down to $19.5 million from $27.6 million and G&A down to $8.3 million from $14.4 million. Cash, cash equivalents and investments stood at $172.8 million at June 30, 2026, which management expects to fund operations at least through 2027.
Key figures
- Revenue
- 3320000
- Guidance
- Cash, cash equivalents and investments of $172.8 million anticipated to be sufficient to fund operations at least through 2027
- Revenue Yoy
- declined to $3.3M in Q2 2026 from $7.9M in Q2 2025
- Total Assets
- 202855000
- Cash Position
- 172798000
- Q2 2025 revenue
- 7874000
- Al137 ind target
- Q1 2027
- Cash dec 31 2025
- 256024000
- Deferred revenue
- 162866000
- Total liabilities
- 212825000
- Q2 2025 ga expense
- 14401000
- Q2 2025 rd expense
- 27611000
- Q2 2026 ga expense
- 8253000
- Q2 2026 rd expense
- 19460000
- Al137 first in human target
- Australia, no later than April 2027
- Weighted avg shares q2 2026
- 111224116
Price after filing
Close on the filing date to close N calendar days later (from $1.54). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.